FDA’s in-house re­view of­fers bleak as­sess­ment of Epizyme’s tazeme­to­stat — but win or lose this can­cer drug may still have a fu­ture

Epizyme will have to over­come a tough as­sess­ment from the FDA’s in-house re­view team for their can­cer drug tazeme­to­stat if they ex­pect to make it to the mar­ket with an OK on ep­ithe­lioid sar­co­ma. But they $EPZM may well have the agency’s on­col­o­gy pan­el on their side, where there’s a built-in bias in fa­vor of even mar­gin­al new drugs when it comes to of­fer­ing physi­cians and pa­tients an­oth­er drug to choose from.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.